Please ensure Javascript is enabled for purposes of website accessibility

Is This Small-Cap Biotech a Buy Before 2020?

By David Haen - Oct 24, 2019 at 1:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.

ChemoCentryx (CCXI 4.56%) develops drugs for orphan diseases, meaning those with fewer than 200,000 patients in the U.S. Currently, ChemoCentryx has four drug candidates in development with the most advanced being avacopan. This quarter, ChemoCentryx will announce pivotal trial results with avacopan in a make-or-break binary event for investors.

Scientist holding pill in tweezers

Source: Getty Images

Avacopan's pivotal phase 3 clinical trial seeks to help patients with anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis. Simply put, the patient's immune system activates a specific type of white blood cells, called neutrophils, that then attack the small blood vessels, causing inflammation and swelling. The irreversible damage can lead to kidney failure. According to ChemoCentryx, ANCA vasculitis afflicts between 40,000 to 75,000 patients in the U.S. and 50,000 to 100,000 patients in Europe.

ANCA vasculitis patients need improved treatment options

Today, ANCA vasculitis patients typically receive high-dose steroids with an immunosuppressant, either cyclophosphamide or Rituxan from Roche Holding. This approach has been around for nearly 50 years.

But steroids, especially when given chronically, can be toxic, and suppressing the immune system can lead to infections. A study published in the Annals of Rheumatic Diseases by Little et al. evaluated data on 524 ANCA vasculitis patients in Europe found 11% of them died within one year, and 59% of those deaths were a result of therapy.

ANCA vasculitis patients clearly need better and safer treatment options. Enter ChemoCentryx and avacopan. The company heralds avacopan as the "most precise mechanism of action" aimed at modulating the complement system.

According to ChemoCentryx, the complement system, one of the components of the immune system, consists of a group of proteins responsible for regulating the defense against bacteria and viruses, triggering inflammation, and removing debris from cells and tissues. Dysregulation of the complement system can cause the body to launch an attack on healthy cells resulting in autoimmune diseases like ANCA vasculitis.  

Avacopan works by specifically inhibiting the C5a receptor. This then prevents the activation of neutrophils, the white blood cells that carry out the attack on the blood vessels in ANCA vasculitis. ChemoCentryx believes the specificity for that receptor benefits patients while leaving the rest of the immune system intact.

Targeting the complement system to fight autoimmune diseases recently emerged as a hotbed for biotechs, including Apellis Pharmaceuticals (APLS 1.57%), Omeros (OMER 12.40%), and Ra Pharmaceuticals (RARX). Earlier this month, Ra announced it was being acquired by Belgian pharma UCB for $2.5 billion, representing a 90% premium to the company's stock price.

Avacopan's pivotal phase 3 trial

The phase 3 trial, scheduled to have results this quarter, aims to achieve two primary endpoints: to determine if the patient achieves remission after 26 weeks of treatment and then if the patient has maintained the remission after 52 weeks. Historically, patients receiving standard-of-care treatment frequently relapse over time. But some analysts caution that 52 weeks may not be long enough to capture the timing of relapses in a real-world setting.

The phase 3 trial is not the typical trial designed to show superiority of one drug over another. Instead, the aim is "non-inferiority" to the standard of care. The company claims that a superiority-based trial requires too many patients to be practical for this rare disease. Instead, it seeks to show comparable efficacy while hopefully demonstrating other benefits such as fewer or less severe side effects and ease of administration with a pill compared to an injection.

Potential headwinds

Payers, including insurance companies, may push back or limit reimbursement due to the non-inferiority design and the argument over whether the endpoint at 52 weeks is too early to see meaningful differences in relapse rates. The alternative treatments will arguably be cheaper, as they are generic and well established. Assuming the trial is positive, ChemoCentryx will need to build an economic argument showing the financial benefit if avacopan delays or prevents relapses, reduces or eliminates the need for steroids, causes fewer side effects including hospitalizations, and improves patients' quality of life.

ChemoCentryx's stock starts to recover

Chemocentryx has a market cap of roughly $450 million. The stock price rebounded nearly 20% over the past few weeks after hitting lows near the end of September. But year to date, the stock is still down about 30%. The company claims avacopan's potential revenue can exceed $1 billion depending on pricing and the number of indications it is ultimately approved to treat. Biotech and pharma stocks trade at a price-to-sales ratio between four to six, according to a 2019 New York University analysis of more than 700 companies. If that is true, then the stock could be worth several multiples and be a good value at these prices. 

Investors can take comfort in the fact that they are owners alongside stalwart investment managers Fidelity and BlackRock as well as healthcare specialist Cormorant Asset Management. Vifor Pharma, a European company specializing in kidney diseases, owns 18.5% as of the proxy statement filed in April 2019. It initially acquired over 6.6% of the stock as part of licensing deals for the rights to avacopan and CCX-140 outside of the U.S. and China. At the end of 2018, Vifor purchased an additional 15% of ChemoCentryx's stock that was owned by GlaxoSmithKline from a partnering arrangement dating back to 2006.

The chances of avacopan successfully meeting the non-inferiority endpoint is probably high. The key metric that investors will need to evaluate is the safety profile. If that looks reasonable or superior to the standard of care, then one can envision doctors and patients wanting to use the drug. And the drug and ChemoCentryx's value should be significantly greater than it is today.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ChemoCentryx, Inc. Stock Quote
ChemoCentryx, Inc.
CCXI
$23.41 (4.56%) $1.02
Omeros Corporation Stock Quote
Omeros Corporation
OMER
$2.72 (12.40%) $0.30
Ra Pharmaceuticals, Inc. Stock Quote
Ra Pharmaceuticals, Inc.
RARX
Apellis Pharmaceuticals, Inc. Stock Quote
Apellis Pharmaceuticals, Inc.
APLS
$42.61 (1.57%) $0.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.